Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - A prospective multicenter observational study

Alimentary Pharmacology and Therapeutics

from Gastroenterology via xlomafota13 on Inoreader http://ift.tt/2d93eAA
via IFTTT